Corrigendum (Age-Related Macular Degeneration Revisited – Piecing the Puzzle: The LXIX Edward Jackson Memorial Lecture (2013) 155(1) (1–35.e13), (S0002939412007635) (10.1016/j.ajo.2012.10.018));Age-related macular degeneration revisited - Piecing the puzzle: The LXIX edward jackson memorial lecture

American Journal of Ophthalmology

Volumn 155, Issue 1, 2013, Pages 1-35.e13

  Miller, Joan W ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; COMPLEMENT; INFLAMMASOME; LIPOFUSCIN;

AGING; ANGIOGENESIS; ARTICLE; CELL ADHESION; CELL DEATH; CELL STRESS; DISEASE COURSE; DRUSEN; ENVIRONMENTAL FACTOR; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENETIC ANALYSIS; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOME; HUMAN; IMMUNE RESPONSE; INFLAMMATION; LIPID METABOLISM; LIPID STORAGE; LIPID TRANSPORT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; VASCULAR RESISTANCE; VISUAL IMPAIRMENT;

EID: 84871180605     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2018.09.023     Document Type: Erratum

References (455)

1. T.J. Liesegang, H.D. Hoskins, and A.D. Jensen The significance of the Edward Jackson lecture Am J Ophthalmol 139 3 2005 530 532
2. World Health Organization. Priority Eye Diseases. Available at http://www.who.int/blindness/causes/priority. Accessed October 1, 2012.
3. P.J. Rosenfeld, D.M. Brown, and J.S. Heier Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1419 1431
4. CATT Research Group D.F. Martin, and M.G. Maguire Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 20 2011 1897 1908
5. D.F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 7 2012 1388 1398
6. R.D. Jager, W.F. Mieler, and J.W. Miller Age-related macular degeneration N Engl J Med 358 24 2008 2606 2617
7. P.T. de Jong Age-related macular degeneration N Engl J Med 355 14 2006 1474 1485
8. M.D. Davis, R.E. Gangnon, and L.Y. Lee The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report no. 17 Arch Ophthalmol 123 11 2005 1484 1498
9. F.L. Ferris, M.D. Davis, and T.E. Clemons A simplified severity scale for age-related macular degeneration: AREDS report no. 18 Arch Ophthalmol 123 11 2005 1570 1574
10. N.M. Bressler, S.B. Bressler, S.K. West, S.L. Fine, and H.R. Taylor The grading and prevalence of macular degeneration in Chesapeake Bay watermen Arch Ophthalmol 107 6 1989 847 852
11. I.C. Munch, B. Sander, and L. Kessel Heredity of small hard drusen in twins aged 20-46 years Invest Ophthalmol Vis Sci 48 2 2007 833 838
12. S.A. Zweifel, R.F. Spaide, C.A. Curcio, G. Malek, and Y. Imamura Reticular pseudodrusen are subretinal drusenoid deposits Ophthalmology 117 2 2010 303 312.e1
13. S. Schmitz-Valckenberg, J.S. Steinberg, M. Fleckenstein, S. Visvalingam, C.K. Brinkmann, and F.G. Holz Combined confocal scanning laser ophthalmoscopy and spectral-domain optical coherence tomography imaging of reticular drusen associated with age-related macular degeneration Ophthalmology 117 6 2010 1169 1176
14. M.L. Klein, P.J. Francis, F.L. Ferris 3rd, S.C. Hamon, and T.E. Clemons Risk assessment model for development of advanced age-related macular degeneration Arch Ophthalmol 129 12 2011 1543 1550
15. G.R. Jackson, C. Owsley, and G. McGwin Jr. Aging and dark adaptation Vision Res 39 23 1999 3975 3982
16. C. Owsley, G. McGwin Jr., G.R. Jackson, K. Kallies, and M. Clark Cone- and rod-mediated dark adaptation impairment in age-related maculopathy Ophthalmology 114 9 2007 1728 1735
17. G.R. Jackson, and J.G. Edwards A short-duration dark adaptation protocol for assessment of age-related maculopathy J Ocul Biol Dis Infor 1 1 2008 7 11
18. C.W. Spraul, G.E. Lang, H.E. Grossniklaus, and G.K. Lang Histologic and morphometric analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in postmortem eyes with age-related macular degeneration and histologic examination of surgically excised choroidal neovascular membranes Surv Ophthalmol 44 Suppl 1 1999 S10 S32
19. C.A. Curcio, and C.L. Millican Basal linear deposit and large drusen are specific for early age-related maculopathy Arch Ophthalmol 117 3 1999 329 339
20. X. Liu, Y. Zhao, and J. Gao Elastic fiber homeostasis requires lysyl oxidase-like 1 protein Nat Genet 36 2 2004 178 182
21. N.H. Chong, J. Keonin, and P.J. Luthert Decreased thickness and integrity of the macular elastic layer of Bruch's membrane correspond to the distribution of lesions associated with age-related macular degeneration Am J Pathol 166 1 2005 241 251
22. R.N. Fariss, S.S. Apte, B.R. Olsen, K. Iwata, and A.H. Milam Tissue inhibitor of metalloproteinases-3 is a component of Bruch's membrane of the eye Am J Pathol 150 1 1997 323 328
23. M. Kamei, and J.G. Hollyfield TIMP-3 in Bruch's membrane: changes during aging and in age-related macular degeneration Invest Ophthalmol Vis Sci 40 10 1999 2367 2375
24. A. Bindewald, S. Schmitz-Valckenberg, and J.J. Jorzik Classification of abnormal fundus autofluorescence patterns in the junctional zone of geographic atrophy in patients with age related macular degeneration Br J Ophthalmol 89 7 2005 874 878
25. S. Schmitz-Valckenberg, A. Bindewald-Wittich, and J. Dolar-Szczasny Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with AMD Invest Ophthalmol Vis Sci 47 6 2006 2648 2654
26. M.E. Hartnett, J.J. Weiter, A. Garsd, and A.E. Jalkh Classification of retinal pigment epithelial detachments associated with drusen Graefes Arch Clin Exp Ophthalmol 230 1 1992 11 19
27. D.M. Monson, J.R. Smith, M.L. Klein, and D.J. Wilson Clinicopathologic correlation of retinal angiomatous proliferation Arch Ophthalmol 126 12 2008 1664 1668
28. K.B. Freund, I.V. Ho, and I.A. Barbazetto Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation Retina 28 2 2008 201 211
29. L.A. Yannuzzi, D.W. Wong, and B.S. Sforzolini Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration Arch Ophthalmol 117 11 1999 1503 1510
30. R. Kawasaki, M. Yasuda, and S.J. Song The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis Ophthalmology 117 5 2010 921 927
31. R.E. Hogg, and U. Chakravarthy Visual function and dysfunction in early and late age-related maculopathy Prog Retin Eye Res 25 3 2006 249 276
32. J.D. Gass Drusen and disciform macular detachment and degeneration Trans Am Ophthalmol Soc 70 1972 409 436
33. H.A. Kahn, H.M. Leibowitz, and J.P. Ganley The Framingham Eye Study. I. Outline and major prevalence findings Am J Epidemiol 106 1 1977 17 32
34. J. Goldberg, G. Flowerdew, E. Smith, J.A. Brody, and M.O. Tso Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Examination Survey Am J Epidemiol 128 4 1988 700 710
35. Eye Disease Case-Control Study Group Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group Arch Ophthalmol 110 12 1992 1701 1708
36. U. Chakravarthy, T.Y. Wong, and A. Fletcher Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis BMC Ophthalmol 10 2010 31
37. S.K. West, F.S. Rosenthal, and N.M. Bressler Exposure to sunlight and other risk factors for age-related macular degeneration Arch Ophthalmol 107 6 1989 875 879
38. H.R. Taylor, S. West, B. Munoz, F.S. Rosenthal, S.B. Bressler, and N.M. Bressler The long-term effects of visible light on the eye Arch Ophthalmol 110 1 1992 99 104
39. M.A. Sandberg, M.J. Tolentino, S. Miller, E.L. Berson, and A.R. Gaudio Hyperopia and neovascularization in age-related macular degeneration Ophthalmology 100 7 1993 1009 1013
40. Age-Related Eye Disease Study Research Group Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study report number 3 Ophthalmology 107 12 2000 2224 2232
41. M.K. Ikram, R. van Leeuwen, J.R. Vingerling, A. Hofman, and P.T. de Jong Relationship between refraction and prevalent as well as incident age-related maculopathy: the Rotterdam Study Invest Ophthalmol Vis Sci 44 9 2003 3778 3782
42. L. Xu, Y. Li, Y. Zheng, and J.B. Jonas Associated factors for age related maculopathy in the adult population in China: the Beijing Eye Study Br J Ophthalmol 90 9 2006 1087 1090
43. T. Boker, T. Fang, and R. Steinmetz Refractive error and choroidal perfusion characteristics in patients with choroidal neovascularization and age-related macular degeneration Ger J Ophthalmol 2 1 1993 10 13
44. Eye Disease Case-Control Study Group Antioxidant status and neovascular age-related macular degeneration. Eye Disease Case-Control Study Group Arch Ophthalmol 111 1 1993 104 109
45. J.M. Seddon, U.A. Ajani, and R.D. Sperduto Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group JAMA 272 18 1994 1413 1420
46. H.A. Kahn, H.M. Leibowitz, and J.P. Ganley The Framingham Eye Study. II. Association of ophthalmic pathology with single variables previously measured in the Framingham Heart Study Am J Epidemiol 106 1 1977 33 41
47. D. Pauleikhoff, C.A. Harper, J. Marshall, and A.C. Bird Aging changes in Bruch's membrane. A histochemical and morphologic study Ophthalmology 97 2 1990 171 178
48. J.R. Wolter, and H.F. Falls Bilateral confluent drusen Arch Ophthalmol 68 1962 219 226
49. C. Starita, A.A. Hussain, S. Pagliarini, and J. Marshall Hydrodynamics of ageing Bruch's membrane: implications for macular disease Exp Eye Res 62 5 1996 565 572
50. C.A. Curcio, M. Johnson, M. Rudolf, and J.D. Huang The oil spill in ageing Bruch membrane Br J Ophthalmol 95 12 2011 1638 1645
51. I. Tabas, K.J. Williams, and J. Boren Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications Circulation 116 16 2007 1832 1844
52. J.W. Ruberti, C.A. Curcio, C.L. Millican, B.P. Menco, J.D. Huang, and M. Johnson Quick-freeze/deep-etch visualization of age-related lipid accumulation in Bruch's membrane Invest Ophthalmol Vis Sci 44 4 2003 1753 1759
53. C.A. Curcio, C.L. Millican, T. Bailey, and H.S. Kruth Accumulation of cholesterol with age in human Bruch's membrane Invest Ophthalmol Vis Sci 42 1 2001 265 274
54. C.A. Curcio Photoreceptor topography in ageing and age-related maculopathy Eye (Lond) 15 Pt 3 2001 376 383
55. E. Friedman, and M.O. Ts'o The retinal pigment epithelium. II. Histologic changes associated with age Arch Ophthalmol 79 3 1968 315 320
56. E. Friedman A hemodynamic model of the pathogenesis of age-related macular degeneration Am J Ophthalmol 124 5 1997 677 682
57. J.S. Friedenwald Contribution to the theory and practice of tonometry Am J Ophthalmol 20 1937 985 1024
58. F.H. Verhoeff, and H.P. Grossman The pathogenesis of disciform degeneration of the macula Trans Am Ophthalmol Soc 35 1937 262 294
59. C.W. Spraul, G.E. Lang, and H.E. Grossniklaus Morphometric analysis of the choroid, Bruch's membrane, and retinal pigment epithelium in eyes with age-related macular degeneration Invest Ophthalmol Vis Sci 37 13 1996 2724 2735
60. E. Friedman The pathogenesis of age-related macular degeneration Am J Ophthalmol 146 3 2008 348 349
61. M.J. Hogan Role of the retinal pigment epithelium in macular disease Trans Am Acad Ophthalmol Otolaryngol 76 1 1972 64 80
62. G.L. Wing, G.C. Blanchard, and J.J. Weiter The topography and age relationship of lipofuscin concentration in the retinal pigment epithelium Invest Ophthalmol Vis Sci 17 7 1978 601 607
63. S. Schmitz-Valckenberg, M. Fleckenstein, H.P. Scholl, and F.G. Holz Fundus autofluorescence and progression of age-related macular degeneration Surv Ophthalmol 54 1 2009 96 117
64. J.R. Sparrow, Y. Wu, T. Nagasaki, K.D. Yoon, K. Yamamoto, and J. Zhou Fundus autofluorescence and the bisretinoids of retina Photochem Photobiol Sci 9 11 2010 1480 1489
65. F.G. Holz, F. Schutt, and J. Kopitz Inhibition of lysosomal degradative functions in RPE cells by a retinoid component of lipofuscin Invest Ophthalmol Vis Sci 40 3 1999 737 743
66. S.C. Finnemann, L.W. Leung, and E. Rodriguez-Boulan The lipofuscin component A2E selectively inhibits phagolysosomal degradation of photoreceptor phospholipid by the retinal pigment epithelium Proc Natl Acad Sci U S A 99 6 2002 3842 3847
67. A. Lakkaraju, S.C. Finnemann, and E. Rodriguez-Boulan The lipofuscin fluorophore A2E perturbs cholesterol metabolism in retinal pigment epithelial cells Proc Natl Acad Sci U S A 104 26 2007 11026 11031
68. J.R. Sparrow, and B. Cai Blue light-induced apoptosis of A2E-containing RPE: involvement of caspase-3 and protection by Bcl-2 Invest Ophthalmol Vis Sci 42 6 2001 1356 1362
69. J. Zhou, S.R. Kim, B.S. Westlund, and J.R. Sparrow Complement activation by bisretinoid constituents of RPE lipofuscin Invest Ophthalmol Vis Sci 50 3 2009 1392 1399
70. J.R. Sparrow, and M. Boulton RPE lipofuscin and its role in retinal pathobiology Exp Eye Res 80 5 2005 595 606
71. H.L. Ramkumar, J. Zhang, and C.C. Chan Retinal ultrastructure of murine models of dry age-related macular degeneration (AMD) Prog Retin Eye Res 29 3 2010 169 190
72. L. Wang, M.E. Clark, and D.K. Crossman Abundant lipid and protein components of drusen PLoS One 5 4 2010 e10329
73. G.J. McKay, C.C. Patterson, and U. Chakravarthy Evidence of association of APOE with age-related macular degeneration: a pooled analysis of 15 studies Hum Mutat 32 12 2011 1407 1416
74. L.V. Johnson, W.P. Leitner, A.J. Rivest, M.K. Staples, M.J. Radeke, and D.H. Anderson The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration Proc Natl Acad Sci U S A 99 18 2002 11830 11835
75. T. Dentchev, A.H. Milam, V.M. Lee, J.Q. Trojanowski, and J.L. Dunaief Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas Mol Vis 9 2003 184 190
76. D.H. Anderson, K.C. Talaga, A.J. Rivest, E. Barron, G.S. Hageman, and L.V. Johnson Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration Exp Eye Res 78 2 2004 243 256
77. L. Paraoan, P. Hiscott, C. Gosden, and I. Grierson Cystatin C in macular and neuronal degenerations: implications for mechanism(s) of age-related macular degeneration Vision Res 50 7 2010 737 742
78. J.D. Ding, L.V. Johnson, and R. Herrmann Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration Proc Natl Acad Sci U S A 108 28 2011 E279 E287
79. T. Yoshida, K. Ohno-Matsui, and S. Ichinose The potential role of amyloid beta in the pathogenesis of age-related macular degeneration J Clin Invest 115 10 2005 2793 2800
80. J. Hoh Kam, E. Lenassi, and G. Jeffery Viewing ageing eyes: diverse sites of amyloid Beta accumulation in the ageing mouse retina and the up-regulation of macrophages PLoS One 5 2010 10
81. F.C. Barouch, and J.W. Miller The role of inflammation and infection in age-related macular degeneration Int Ophthalmol Clin 47 2 2007 185 197
82. G.S. Hageman, P.J. Luthert, N.H. Victor Chong, L.V. Johnson, D.H. Anderson, and R.F. Mullins An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration Prog Retin Eye Res 20 6 2001 705 732
83. D.H. Anderson, R.F. Mullins, G.S. Hageman, and L.V. Johnson A role for local inflammation in the formation of drusen in the aging eye Am J Ophthalmol 134 3 2002 411 431
84. P.L. Penfold, M.C. Killingsworth, and S.H. Sarks Senile macular degeneration. The involvement of giant cells in atrophy of the retinal pigment epithelium Invest Ophthalmol Vis Sci 27 3 1986 364 371
85. P.L. Penfold, M.C. Killingsworth, and S.H. Sarks Senile macular degeneration: the involvement of immunocompetent cells Graefes Arch Clin Exp Ophthalmol 223 2 1985 69 76
86. P.L. Penfold, S.C. Liew, M.C. Madigan, and J.M. Provis Modulation of major histocompatibility complex class II expression in retinas with age-related macular degeneration Invest Ophthalmol Vis Sci 38 10 1997 2125 2133
87. Ma W, Coon S, Zhao L, Fariss RN, Wong WT. A2E accumulation influences retinal microglial activation and complement regulation. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2012.06.010.
88. P.L. Penfold, J.M. Provis, J.H. Furby, P.A. Gatenby, and F.A. Billson Autoantibodies to retinal astrocytes associated with age-related macular degeneration Graefes Arch Clin Exp Ophthalmol 228 3 1990 270 274
89. D.H. Gurne, M.O. Tso, D.P. Edward, and H. Ripps Antiretinal antibodies in serum of patients with age-related macular degeneration Ophthalmology 98 5 1991 602 607
90. N. Patel, M. Ohbayashi, and A.K. Nugent Circulating anti-retinal antibodies as immune markers in age-related macular degeneration Immunology 115 3 2005 422 430
91. D.A. Newsome, A.T. Hewitt, W. Huh, P.G. Robey, and J.R. Hassell Detection of specific extracellular matrix molecules in drusen, Bruch's membrane, and ciliary body Am J Ophthalmol 104 4 1987 373 381
92. L.V. Johnson, S. Ozaki, M.K. Staples, P.A. Erickson, and D.H. Anderson A potential role for immune complex pathogenesis in drusen formation Exp Eye Res 70 4 2000 441 449
93. R.F. Mullins, S.R. Russell, D.H. Anderson, and G.S. Hageman Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease FASEB J 14 7 2000 835 846
94. D.H. Anderson, M.J. Radeke, and N.B. Gallo The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited Prog Retin Eye Res 29 2 2010 95 112
95. J. Ambati, A. Anand, and S. Fernandez An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice Nat Med 9 11 2003 1390 1397
96. U.F. Luhmann, S. Robbie, and P.M. Munro The drusenlike phenotype in aging Ccl2-knockout mice is caused by an accelerated accumulation of swollen autofluorescent subretinal macrophages Invest Ophthalmol Vis Sci 50 12 2009 5934 5943
97. Y. Zhou, K.G. Sheets, and E.J. Knott Cellular and 3D optical coherence tomography assessment during the initiation and progression of retinal degeneration in the Ccl2/Cx3cr1-deficient mouse Exp Eye Res 93 5 2011 636 648
98. U.F. Luhmann, C.A. Lange, and S. Robbie Differential modulation of retinal degeneration by Ccl2 and Cx3cr1 chemokine signalling PLoS One 7 4 2012 e35551
99. M.J. Mattapallil, E.F. Wawrousek, and C.C. Chan The Rd8 mutation of the Crb1 gene is present in vendor lines of C57BL/6N mice and embryonic stem cells, and confounds ocular induced mutant phenotypes Invest Ophthalmol Vis Sci 53 6 2012 2921 2927
100. M. Lamkanfi Emerging inflammasome effector mechanisms Nat Rev Immunol 11 3 2011 213 220
101. O. Takeuchi, and S. Akira Pattern recognition receptors and inflammation Cell 140 6 2010 805 820
102. A. Dunne Inflammasome activation: from inflammatory disease to infection Biochem Soc Trans 39 2 2011 669 673
103. V. Tarallo, Y. Hirano, and B.D. Gelfand DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88 Cell 149 4 2012 847 859
104. S.L. Doyle, M. Campbell, and E. Ozaki NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components Nat Med 18 5 2012 791 798
105. H. Qiao, K.H. Sonoda, and Y. Ikeda Interleukin-18 regulates pathological intraocular neovascularization J Leukoc Biol 81 4 2007 1012 1021
106. S. Ishida, T. Usui, and K. Yamashiro VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization J Exp Med 198 3 2003 483 489
107. D. Ricklin, G. Hajishengallis, K. Yang, and J.D. Lambris Complement: a key system for immune surveillance and homeostasis Nat Immunol 11 9 2010 785 797
108. M.A. Hadders, D. Bubeck, and P. Roversi Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9 Cell Rep 1 2012 1 8
109. J.L. Haines, M.A. Hauser, and S. Schmidt Complement factor H variant increases the risk of age-related macular degeneration Science 308 5720 2005 419 421
110. A.O. Edwards, R. Ritter 3rd, K.J. Abel, A. Manning, C. Panhuysen, and L.A. Farrer Complement factor H polymorphism and age-related macular degeneration Science 308 5720 2005 421 424
111. R.J. Klein, C. Zeiss, and E.Y. Chew Complement factor H polymorphism in age-related macular degeneration Science 308 5720 2005 385 389
112. G.S. Hageman, D.H. Anderson, and L.V. Johnson A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration Proc Natl Acad Sci U S A 102 20 2005 7227 7232
113. S. Zareparsi, K.E. Branham, and M. Li Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration Am J Hum Genet 77 1 2005 149 153
114. L.V. Johnson, D.L. Forest, and C.D. Banna Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration Proc Natl Acad Sci U S A 108 45 2011 18277 18282
115. M. Nozaki, B.J. Raisler, and E. Sakurai Drusen complement components C3a and C5a promote choroidal neovascularization Proc Natl Acad Sci U S A 103 7 2006 2328 2333
116. R. Kurihara, K. Yamaoka, and N. Sawamukai C5a promotes migration, proliferation, and vessel formation in endothelial cells Inflamm Res 59 8 2010 659 666
117. D.N. Cortright, R. Meade, S.M. Waters, B.L. Chenard, and J.E. Krause C5a, but not C3a, increases VEGF secretion in ARPE-19 human retinal pigment epithelial cells Curr Eye Res 34 1 2009 57 61
118. P.S. Bora, J.H. Sohn, and J.M. Cruz Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization J Immunol 174 1 2005 491 497
119. N.S. Bora, S. Kaliappan, and P. Jha Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H J Immunol 177 3 2006 1872 1878
120. N.S. Bora, S. Kaliappan, and P. Jha CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration J Immunol 178 3 2007 1783 1790
121. B. Rohrer, B. Coughlin, and K. Kunchithapautham The alternative pathway is required, but not alone sufficient, for retinal pathology in mouse laser-induced choroidal neovascularization Mol Immunol 48 6-7 2011 e1 e8
122. S.M. Cashman, K. Ramo, and R. Kumar-Singh A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration PLoS One 6 4 2011 e19078
123. B. Rohrer, Q. Long, and B. Coughlin A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration Invest Ophthalmol Vis Sci 50 7 2009 3056 3064
124. H.F. Langer, K.J. Chung, and V.V. Orlova Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis Blood 116 22 2010 4395 4403
125. G.B. Appel, H.T. Cook, and G. Hageman Membranoproliferative glomerulonephritis type II (dense deposit disease): an update J Am Soc Nephrol 16 5 2005 1392 1403
126. Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor A in intraocular vascular disease. Ophthalmology. doi:10.1016/j.ophtha.2012.07.038.
127. G. Trichonas, Y. Murakami, and A. Thanos Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis Proc Natl Acad Sci U S A 107 50 2010 21695 21700
128. Y. Murakami, H. Matsumoto, and M. Roh Receptor interacting protein kinase mediates necrotic cone but not rod cell death in a mouse model of inherited degeneration Proc Natl Acad Sci U S A 109 36 2012 14598 14603
129. J. Francois [The inheritance of senile macule degeneration] Ophthalmologica 175 2 1977 67 72
130. G. Silvestri, P.B. Johnston, and A.E. Hughes Is genetic predisposition an important risk factor in age-related macular degeneration? Eye (Lond) 8 Pt 5 1994 564 568
131. J.M. Seddon, U.A. Ajani, and B.D. Mitchell Familial aggregation of age-related maculopathy Am J Ophthalmol 123 2 1997 199 206
132. C.C. Klaver, R.C. Wolfs, J.J. Assink, C.M. van Duijn, A. Hofman, and P.T. de Jong Genetic risk of age-related maculopathy. Population-based familial aggregation study Arch Ophthalmol 116 12 1998 1646 1651
133. S.M. Meyers, T. Greene, and F.A. Gutman A twin study of age-related macular degeneration Am J Ophthalmol 120 6 1995 757 766
134. L. Luo, J. Harmon, and X. Yang Familial aggregation of age-related macular degeneration in the Utah population Vision Res 48 3 2008 494 500
135. M.M. Deangelis, A.C. Silveira, E.A. Carr, and I.K. Kim Genetics of age-related macular degeneration: current concepts, future directions Semin Ophthalmol 26 3 2011 77 93
136. D.S. Friedman, B.J. O'Colmain, and B. Munoz Prevalence of age-related macular degeneration in the United States Arch Ophthalmol 122 4 2004 564 572
137. R.L. Ufret-Vincenty, B. Aredo, and X. Liu Transgenic mice expressing variants of complement factor H develop AMD-like retinal findings Invest Ophthalmol Vis Sci 51 11 2010 5878 5887
138. D.D. Despriet, C.C. Klaver, and J.C. Witteman Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration JAMA 296 3 2006 301 309
139. A. Thakkinstian, P. Han, and M. McEvoy Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration Hum Mol Genet 15 18 2006 2784 2790
140. C.L. Thompson, B.E. Klein, and R. Klein Complement factor H and hemicentin-1 in age-related macular degeneration and renal phenotypes Hum Mol Genet 16 17 2007 2135 2148
141. N. Kondo, H. Bessho, S. Honda, and A. Negi Complement factor H Y402H variant and risk of age-related macular degeneration in Asians: a systematic review and meta-analysis Ophthalmology 118 2 2011 339 344
142. Y.L. Quan, A.Y. Zhou, and Z.H. Feng Association between complementary factor H Y402H polymorphisms and age-related macular degeneration in Chinese: systematic review and meta-analysis Int J Ophthalmol 5 2 2012 242 246
143. S. Raychaudhuri, O. Iartchouk, and K. Chin A rare penetrant mutation in CFH confers high risk of age-related macular degeneration Nat Genet 43 12 2011 1232 1236
144. H. Chen, K. Liu, L.J. Chen, P. Hou, W. Chen, and C.P. Pang Genetic associations in polypoidal choroidal vasculopathy: a systematic review and meta-analysis Mol Vis 18 2012 816 829
145. M. Jozsi, and P.F. Zipfel Factor H family proteins and human diseases Trends Immunol 29 8 2008 380 387
146. S. Heinen, A. Hartmann, and N. Lauer Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation Blood 114 12 2009 2439 2447
147. A.E. Hughes, N. Orr, H. Esfandiary, M. Diaz-Torres, T. Goodship, and U. Chakravarthy A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration Nat Genet 38 10 2006 1173 1177
148. S. Raychaudhuri, S. Ripke, and M. Li Associations of CFHR1-CFHR3 deletion and a CFH SNP to age-related macular degeneration are not independent Nat Genet 42 7 2010 553 555 author reply 555-556
149. S. Cantsilieris, S.J. White, A.J. Richardson, R.H. Guymer, and P.N. Baird Comprehensive analysis of copy number variation of genes at chromosome 1 and 10 loci associated with late age related macular degeneration PLoS One 7 4 2012 e35255
150. U. Amara, M.A. Flierl, and D. Rittirsch Molecular intercommunication between the complement and coagulation systems J Immunol 185 9 2010 5628 5636
151. Z. Bagoly, E. Katona, and L. Muszbek Factor XIII and inflammatory cells Thromb Res 129 Suppl 2 2012 S77 S81
152. H. Zhang, M.A. Morrison, and A. Dewan The NEI/NCBI dbGAP database: genotypes and haplotypes that may specifically predispose to risk of neovascular age-related macular degeneration BMC Med Genet 9 2008 51
153. J. Jakobsdottir, Y.P. Conley, D.E. Weeks, T.S. Mah, R.E. Ferrell, and M.B. Gorin Susceptibility genes for age-related maculopathy on chromosome 10q26 Am J Hum Genet 77 3 2005 389 407
154. I. Landego, N. Jayachandran, and S. Wullschleger Interaction of TAPP adapter proteins with phosphatidylinositol (3,4)-bisphosphate regulates B-cell activation and autoantibody production Eur J Immunol 42 10 2012 2760 2770
155. E. Kortvely, S.M. Hauck, and G. Duetsch ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degenerations Invest Ophthalmol Vis Sci 51 1 2010 79 88
156. A. Kanda, W. Chen, and M. Othman A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration Proc Natl Acad Sci U S A 104 41 2007 16227 16232
157. L.G. Fritsche, T. Loenhardt, and A. Janssen Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA Nat Genet 40 7 2008 892 896
158. S.G. Jarrett, A.S. Lewin, and M.E. Boulton The importance of mitochondria in age-related and inherited eye disorders Ophthalmic Res 44 3 2010 179 190
159. A. Dewan, M. Liu, and S. Hartman HTRA1 promoter polymorphism in wet age-related macular degeneration Science 314 5801 2006 989 992
160. Z. Yang, N.J. Camp, and H. Sun A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration Science 314 5801 2006 992 993
161. A. Jones, S. Kumar, and N. Zhang Increased expression of multifunctional serine protease, HTRA1, in retinal pigment epithelium induces polypoidal choroidal vasculopathy in mice Proc Natl Acad Sci U S A 108 35 2011 14578 14583
162. T. Clausen, M. Kaiser, R. Huber, and M. Ehrmann HTRA proteases: regulated proteolysis in protein quality control Nat Rev Mol Cell Biol 12 3 2011 152 162
163. S. Vierkotten, P.S. Muether, and S. Fauser Overexpression of HTRA1 leads to ultrastructural changes in the elastic layer of Bruch's membrane via cleavage of extracellular matrix components PLoS One 6 8 2011 e22959
164. J. Zumbrunn, and B. Trueb Primary structure of a putative serine protease specific for IGF-binding proteins FEBS Lett 398 2-3 1996 187 192
165. W. Chao, and P.A. D'Amore IGF2: epigenetic regulation and role in development and disease Cytokine Growth Factor Rev 19 2 2008 111 120
166. L. Sobrin, S. Ripke, and Y. Yu Heritability and genome-wide association study to assess genetic differences between advanced age-related macular degeneration subtypes Ophthalmology 119 9 2012 1874 1885
167. L. Zhang, S.L. Lim, and H. Du High temperature requirement factor A1 (HTRA1) gene regulates angiogenesis through transforming growth factor-beta family member growth differentiation factor 6 J Biol Chem 287 2 2012 1520 1526
168. S. Launay, E. Maubert, and N. Lebeurrier HtrA1-dependent proteolysis of TGF-beta controls both neuronal maturation and developmental survival Cell Death Differ 15 9 2008 1408 1416
169. A. Tennstaedt, S. Popsel, and L. Truebestein Human high temperature requirement serine protease A1 (HTRA1) degrades tau protein aggregates J Biol Chem 287 25 2012 20931 20941
170. K.U. Loffler, D.P. Edward, and M.O. Tso Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina Invest Ophthalmol Vis Sci 36 1 1995 24 31
171. C. Sun, M. Zhao, and X. Li CFB/C2 gene polymorphisms and risk of age-related macular degeneration: a systematic review and meta-analysis Curr Eye Res 37 4 2012 259 271
172. A. Thakkinstian, M. McEvoy, and U. Chakravarthy The association between complement component 2/complement factor B polymorphisms and age-related macular degeneration: a HuGE review and meta-analysis Am J Epidemiol 176 5 2012 361 372
173. X. Yuan, X. Gu, and J.S. Crabb Quantitative proteomics: comparison of the macular Bruch membrane/choroid complex from age-related macular degeneration and normal eyes Mol Cell Proteomics 9 6 2010 1031 1046
174. E. An, X. Lu, and J. Flippin Secreted proteome profiling in human RPE cell cultures derived from donors with age related macular degeneration and age matched healthy donors J Proteome Res 5 10 2006 2599 2610
175. A. Thakkinstian, G.J. McKay, and M. McEvoy Systematic review and meta-analysis of the association between complement component 3 and age-related macular degeneration: a HuGE review and meta-analysis Am J Epidemiol 173 12 2011 1365 1379
176. C.M. Stanton, J.R. Yates, and A.I. den Hollander Complement factor D in age-related macular degeneration Invest Ophthalmol Vis Sci 52 12 2011 8828 8834
177. Y. Yu, T.R. Bhangale, and J. Fagerness Common variants near FRK/COL10A1 and VEGFA are associated with advanced age-related macular degeneration Hum Mol Genet 20 18 2011 3699 3709
178. R.F. Mullins, E.A. Faidley, H.T. Daggett, C. Jomary, A.J. Lotery, and E.M. Stone Localization of complement 1 inhibitor (C1INH/SERPING1) in human eyes with age-related macular degeneration Exp Eye Res 89 5 2009 767 773
179. S. Ennis, C. Jomary, and R. Mullins Association between the SERPING1 gene and age-related macular degeneration: a two-stage case-control study Lancet 372 9652 2008 1828 1834
180. G. Jun, M. Nicolaou, and M.A. Morrison Influence of ROBO1 and RORA on risk of age-related macular degeneration reveals genetically distinct phenotypes in disease pathophysiology PLoS One 6 10 2011 e25775
181. A.C. Silveira, M.A. Morrison, and F. Ji Convergence of linkage, gene expression and association data demonstrates the influence of the RAR-related orphan receptor alpha (RORA) gene on neovascular AMD: a systems biology based approach Vision Res 50 7 2010 698 715
182. D.A. Schaumberg, D. Chasman, and M.A. Morrison Prospective study of common variants in the retinoic acid receptor-related orphan receptor alpha gene and risk of neovascular age-related macular degeneration Arch Ophthalmol 128 11 2010 1462 1471
183. P. Delerive, D. Monte, and G. Dubois The orphan nuclear receptor ROR alpha is a negative regulator of the inflammatory response EMBO Rep 2 1 2001 42 48
184. F. Boukhtouche, J. Mariani, and A. Tedgui The "CholesteROR" protective pathway in the vascular system Arterioscler Thromb Vasc Biol 24 4 2004 637 643
185. R.L. Fitzsimmons, P. Lau, and G.E. Muscat Retinoid-related orphan receptor alpha and the regulation of lipid homeostasis J Steroid Biochem Mol Biol 130 3-5 2012 159 168
186. C. Chauvet, B. Bois-Joyeux, E. Berra, J. Pouyssegur, and J.L. Danan The gene encoding human retinoic acid-receptor-related orphan receptor alpha is a target for hypoxia-inducible factor 1 Biochem J 384 Pt 1 2004 79 85
187. S. Besnard, J.S. Silvestre, and M. Duriez Increased ischemia-induced angiogenesis in the staggerer mouse, a mutant of the nuclear receptor Roralpha Circ Res 89 12 2001 1209 1215
188. Y. Zhu, S. McAvoy, R. Kuhn, and D.I. Smith RORA, a large common fragile site gene, is involved in cellular stress response Oncogene 25 20 2006 2901 2908
189. J. Tuo, B.C. Smith, and C.M. Bojanowski The involvement of sequence variation and expression of CX3CR1 in the pathogenesis of age-related macular degeneration FASEB J 18 11 2004 1297 1299
190. C. Combadiere, C. Feumi, and W. Raoul CX3CR1-dependent subretinal microglia cell accumulation is associated with cardinal features of age-related macular degeneration J Clin Invest 117 10 2007 2920 2928
191. J. Tuo, C.M. Bojanowski, and M. Zhou Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration Invest Ophthalmol Vis Sci 48 8 2007 3827 3836
192. Y. Wang, D. Shen, and V.M. Wang Enhanced apoptosis in retinal pigment epithelium under inflammatory stimuli and oxidative stress Apoptosis 17 11 2012 1144 1155
193. S.V. Goverdhan, S.I. Khakoo, H. Gaston, X. Chen, and A.J. Lotery Age-related macular degeneration is associated with the HLA-Cw*0701 genotype and the natural killer cell receptor AA haplotype Invest Ophthalmol Vis Sci 49 11 2008 5077 5082
194. K.W. Leung, C.J. Barnstable, and J. Tombran-Tink Bacterial endotoxin activates retinal pigment epithelial cells and induces their degeneration through IL-6 and IL-8 autocrine signaling Mol Immunol 46 7 2009 1374 1386
195. J.B. Jonas, Y. Tao, M. Neumaier, and P. Findeisen Cytokine concentration in aqueous humour of eyes with exudative age-related macular degeneration Acta Ophthalmol 90 5 2012 e381 e388
196. S.V. Goverdhan, S. Ennis, and S.R. Hannan Interleukin-8 promoter polymorphism -251A/T is a risk factor for age-related macular degeneration Br J Ophthalmol 92 4 2008 537 540
197. Z. Yang, C. Stratton, and P.J. Francis Toll-like receptor 3 and geographic atrophy in age-related macular degeneration N Engl J Med 359 14 2008 1456 1463
198. S. Zareparsi, M. Buraczynska, and K.E. Branham Toll-like receptor 4 variant D299G is associated with susceptibility to age-related macular degeneration Hum Mol Genet 14 11 2005 1449 1455
199. T. Nakamura, P.R. Lozano, and Y. Ikeda Fibulin-5/DANCE is essential for elastogenesis in vivo Nature 415 6868 2002 171 175
200. H. Yanagisawa, E.C. Davis, and B.C. Starcher Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo Nature 415 6868 2002 168 171
201. R.F. Mullins, M.A. Olvera, A.F. Clark, and E.M. Stone Fibulin-5 distribution in human eyes: relevance to age-related macular degeneration Exp Eye Res 84 2 2007 378 380
202. J.A. Spencer, S.L. Hacker, and E.C. Davis Altered vascular remodeling in fibulin-5-deficient mice reveals a role of fibulin-5 in smooth muscle cell proliferation and migration Proc Natl Acad Sci U S A 102 8 2005 2946 2951
203. M.L. Klein, D.W. Schultz, and A. Edwards Age-related macular degeneration. Clinical features in a large family and linkage to chromosome 1q Arch Ophthalmol 116 8 1998 1082 1088
204. D.W. Schultz, M.L. Klein, and A.J. Humpert Analysis of the ARMD1 locus: evidence that a mutation in HEMICENTIN-1 is associated with age-related macular degeneration in a large family Hum Mol Genet 12 24 2003 3315 3323
205. E.M. Stone, A.J. Lotery, and F.L. Munier A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy Nat Genet 22 2 1999 199 202
206. R. Klein, M.D. Knudtson, K.E. Lee, and B.E. Klein Serum cystatin C level, kidney disease markers, and incidence of age-related macular degeneration: the Beaver Dam Eye Study Arch Ophthalmol 127 2 2009 193 199
207. J. Zurdel, U. Finckh, G. Menzer, R.M. Nitsch, and G. Richard CST3 genotype associated with exudative age related macular degeneration Br J Ophthalmol 86 2 2002 214 219
208. B. Tizon, E.M. Ribe, W. Mi, C.M. Troy, and E. Levy Cystatin C protects neuronal cells from amyloid-beta-induced toxicity J Alzheimers Dis 19 3 2010 885 894
209. N.E. Clarke, M.J. Fisher, K.E. Porter, D.W. Lambert, and A.J. Turner Angiotensin converting enzyme (ACE) and ACE2 bind integrins and ACE2 regulates integrin signalling PLoS One 7 4 2012 e34747
210. S. Sarlos, B. Rizkalla, C.J. Moravski, Z. Cao, M.E. Cooper, and J.L. Wilkinson-Berka Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin Am J Pathol 163 3 2003 879 887
211. H.K. Hamdi, J. Reznik, and R. Castellon Alu DNA polymorphism in ACE gene is protective for age-related macular degeneration Biochem Biophys Res Commun 295 3 2002 668 672
212. G.A. Plenz, M.C. Deng, H. Robenek, and W. Volker Vascular collagens: spotlight on the role of type VIII collagen in atherogenesis Atherosclerosis 166 1 2003 1 11
213. P. Rooney, M. Wang, P. Kumar, and S. Kumar Angiogenic oligosaccharides of hyaluronan enhance the production of collagens by endothelial cells J Cell Sci 105 Pt 1 1993 213 218
214. K.G. Duncan, K. Hosseini, and K.R. Bailey Expression of reverse cholesterol transport proteins ATP-binding cassette A1 (ABCA1) and scavenger receptor BI (SR-BI) in the retina and retinal pigment epithelium Br J Ophthalmol 93 8 2009 1116 1120
215. Y. Yu, R. Reynolds, J. Fagerness, B. Rosner, M.J. Daly, and J.M. Seddon Association of variants in the LIPC and ABCA1 genes with intermediate and large drusen and advanced age-related macular degeneration Invest Ophthalmol Vis Sci 52 7 2011 4663 4670
216. A. Maeda, T. Maeda, M. Golczak, and K. Palczewski Retinopathy in mice induced by disrupted all-trans-retinal clearance J Biol Chem 283 39 2008 26684 26693
217. H. Sun, and J. Nathans ABCR, the ATP-binding cassette transporter responsible for Stargardt macular dystrophy, is an efficient target of all-trans-retinal-mediated photooxidative damage in vitro. Implications for retinal disease J Biol Chem 276 15 2001 11766 11774
218. F. Quazi, S. Lenevich, and R.S. Molday ABCA4 is an N-retinylidene- phosphatidylethanolamine and phosphatidylethanolamine importer Nat Commun 3 2012 925
219. R. Allikmets, N. Singh, and H. Sun A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy Nat Genet 15 3 1997 236 246
220. N. Patel, T. Adewoyin, and N.V. Chong Age-related macular degeneration: a perspective on genetic studies Eye (Lond) 22 6 2008 768 776
221. J. Weng, N.L. Mata, S.M. Azarian, R.T. Tzekov, D.G. Birch, and G.H. Travis Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice Cell 98 1 1999 13 23
222. N.L. Mata, R.T. Tzekov, X. Liu, J. Weng, D.G. Birch, and G.H. Travis Delayed dark-adaptation and lipofuscin accumulation in abcr+/- mice: implications for involvement of ABCR in age-related macular degeneration Invest Ophthalmol Vis Sci 42 8 2001 1685 1690
223. H.P. Scholl, H. Langrova, B.H. Weber, E. Zrenner, and E. Apfelstedt-Sylla Clinical electrophysiology of two rod pathways: normative values and clinical application Graefes Arch Clin Exp Ophthalmol 239 2 2001 71 80
224. D.G. Birch, A.Y. Peters, K.L. Locke, R. Spencer, C.F. Megarity, and G.H. Travis Visual function in patients with cone-rod dystrophy (CRD) associated with mutations in the ABCA4(ABCR) gene Exp Eye Res 73 6 2001 877 886
225. R.W. Mahley, K.H. Weisgraber, and Y. Huang Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease Proc Natl Acad Sci U S A 103 15 2006 5644 5651
226. F. Bonomini, F. Filippini, and T. Hayek Apolipoprotein E and its role in aging and survival Exp Gerontol 45 2 2010 149 157
227. N. Tserentsoodol, N.V. Gordiyenko, I. Pascual, J.W. Lee, S.J. Fliesler, and I.R. Rodriguez Intraretinal lipid transport is dependent on high density lipoprotein-like particles and class B scavenger receptors Mol Vis 12 2006 1319 1333
228. N. Parekh, R.J. Chappell, A.E. Millen, D.M. Albert, and J.A. Mares Association between vitamin D and age-related macular degeneration in the Third National Health and Nutrition Examination Survey, 1988 through 1994 Arch Ophthalmol 125 5 2007 661 669
229. A.V. Krishnan, and D. Feldman Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D Annu Rev Pharmacol Toxicol 51 2011 311 336
230. M.A. Morrison, A.C. Silveira, and N. Huynh Systems biology-based analysis implicates a novel role for vitamin D metabolism in the pathogenesis of age-related macular degeneration Hum Genomics 5 6 2011 538 568
231. Y.P. Conley, J. Jakobsdottir, and T. Mah CFH, ELOVL4, PLEKHA1 and LOC387715 genes and susceptibility to age-related maculopathy: AREDS and CHS cohorts and meta-analyses Hum Mol Genet 15 21 2006 3206 3218
232. Y.P. Conley, A. Thalamuthu, and J. Jakobsdottir Candidate gene analysis suggests a role for fatty acid biosynthesis and regulation of the complement system in the etiology of age-related maculopathy Hum Mol Genet 14 14 2005 1991 2002
233. S. Fauser, D. Smailhodzic, and A. Caramoy Evaluation of serum lipid concentrations and genetic variants at high-density lipoprotein metabolism loci and TIMP3 in age-related macular degeneration Invest Ophthalmol Vis Sci 52 8 2011 5525 5528
234. J.L. Haines, N. Schnetz-Boutaud, and S. Schmidt Functional candidate genes in age-related macular degeneration: significant association with VEGF, VLDLR, and LRP6 Invest Ophthalmol Vis Sci 47 1 2006 329 335
235. Y.T. Lechanteur, J.P. van de Ven, and D. Smailhodzic Genetic, behavioral, and sociodemographic risk factors for second eye progression in age-related macular degeneration Invest Ophthalmol Vis Sci 53 9 2012 5846 5852
236. D.W. Dawson, O.V. Volpert, and P. Gillis Pigment epithelium-derived factor: a potent inhibitor of angiogenesis Science 285 5425 1999 245 248
237. N.M. Holekamp, N. Bouck, and O. Volpert Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration Am J Ophthalmol 134 2 2002 220 227
238. J.M. Lin, L. Wan, and Y.Y. Tsai Pigment epithelium-derived factor gene Met72Thr polymorphism is associated with increased risk of wet age-related macular degeneration Am J Ophthalmol 145 4 2008 716 721
239. I. Nakata, K. Yamashiro, and R. Yamada Genetic variants in pigment epithelium-derived factor influence response of polypoidal choroidal vasculopathy to photodynamic therapy Ophthalmology 118 7 2011 1408 1415
240. P.J. Francis, S.C. Hamon, J. Ott, R.G. Weleber, and M.L. Klein Polymorphisms in C2, CFB and C3 are associated with progression to advanced age related macular degeneration associated with visual loss J Med Genet 46 5 2009 300 307
241. A.J. Churchill, J.G. Carter, and H.C. Lovell VEGF polymorphisms are associated with neovascular age-related macular degeneration Hum Mol Genet 15 19 2006 2955 2961
242. C. Li, Z. Huang, and R. Kingsley Biochemical alterations in the retinas of very low-density lipoprotein receptor knockout mice: an animal model of retinal angiomatous proliferation Arch Ophthalmol 125 6 2007 795 803
243. M.I. Dorrell, E. Aguilar, and R. Jacobson Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization- associated oxidative stress J Clin Invest 119 3 2009 611 623
244. Y. Chen, Y. Hu, K. Lu, J.G. Flannery, and J.X. Ma Very low density lipoprotein receptor, a negative regulator of the wnt signaling pathway and choroidal neovascularization J Biol Chem 282 47 2007 34420 34428
245. K. Kessenbrock, V. Plaks, and Z. Werb Matrix metalloproteinases: regulators of the tumor microenvironment Cell 141 1 2010 52 67
246. R. Sharma, Y. Yang, A. Sharma, S. Awasthi, and Y.C. Awasthi Antioxidant role of glutathione S-transferases: protection against oxidant toxicity and regulation of stress-mediated apoptosis Antioxid Redox Signal 6 2 2004 289 300
247. L. Miao, and D.K. St Clair Regulation of superoxide dismutase genes: implications in disease Free Radic Biol Med 47 4 2009 344 356
248. K. Kimura, Y. Isashiki, S. Sonoda, T. Kakiuchi-Matsumoto, and N. Ohba Genetic association of manganese superoxide dismutase with exudative age-related macular degeneration Am J Ophthalmol 130 6 2000 769 773
249. X. He, P. Hahn, and J. Iacovelli Iron homeostasis and toxicity in retinal degeneration Prog Retin Eye Res 26 6 2007 649 673
250. D. Wysokinski, J. Szaflik, and A. Sklodowska The A Allele of the -576G>A polymorphism of the transferrin gene is associated with the increased risk of age-related macular degeneration in smokers Tohoku J Exp Med 223 4 2011 253 261
251. A.M. Newman, N.B. Gallo, and L.S. Hancox Systems-level analysis of age-related macular degeneration reveals global biomarkers and phenotype-specific functional networks Genome Med 4 2 2012 16
252. S. Kuny, F. Gaillard, and Y. Sauve Differential gene expression in eyecup and retina of a mouse model of Stargardt-like macular dystrophy (STGD3) Invest Ophthalmol Vis Sci 53 2 2012 664 675
253. M.M. DeAngelis, F. Ji, and I.K. Kim Cigarette smoking, CFH, APOE, ELOVL4, and risk of neovascular age-related macular degeneration Arch Ophthalmol 125 1 2007 49 54
254. M. Feehan, J. Hartman, and R. Durante Identifying subtypes of patients with neovascular age-related macular degeneration by genotypic and cardiovascular risk characteristics BMC Med Genet 12 2011 83
255. J.M. Seddon, R. Reynolds, J. Maller, J.A. Fagerness, M.J. Daly, and B. Rosner Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables Invest Ophthalmol Vis Sci 50 5 2009 2044 2053
256. J.M. Seddon, R. Reynolds, Y. Yu, M.J. Daly, and B. Rosner Risk models for progression to advanced age-related macular degeneration using demographic, environmental, genetic, and ocular factors Ophthalmology 118 11 2011 2203 2211
257. B. Zanke, S. Hawken, R. Carter, and D. Chow A genetic approach to stratification of risk for age-related macular degeneration Can J Ophthalmol 45 1 2010 22 27
258. G.S. Ying, and M.G. Maguire Development of a risk score for geographic atrophy in complications of the age-related macular degeneration prevention trial Ophthalmology 118 2 2011 332 338
259. P.J. Francis, and M.L. Klein Update on the role of genetics in the onset of age-related macular degeneration Clin Ophthalmol 5 2011 1127 1133
260. M.A. Brantley Jr., A.M. Fang, J.M. King, A. Tewari, S.M. Kymes, and A. Shiels Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab Ophthalmology 114 12 2007 2168 2173
261. A.Y. Lee, A.K. Raya, S.M. Kymes, A. Shiels, and M.A. Brantley Jr. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab Br J Ophthalmol 93 5 2009 610 613
262. M.L. Klein, P.J. Francis, and B. Rosner CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration Ophthalmology 115 6 2008 1019 1025
263. F. Parmeggiani, C. Costagliola, and D. Gemmati Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration Pharmacogenet Genomics 17 12 2007 1039 1046
264. F. Parmeggiani, C. Costagliola, and D. Gemmati Coagulation gene predictors of photodynamic therapy for occult choroidal neovascularization in age-related macular degeneration Invest Ophthalmol Vis Sci 49 7 2008 3100 3106
265. F. Parmeggiani, D. Gemmati, C. Costagliola, A. Sebastiani, and C. Incorvaia Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration Pharmacogenomics 10 1 2009 81 95
266. B.S. Shastry Pharmacogenomics in ophthalmology Discov Med 12 63 2011 159 167
267. H. Chen, K.D. Yu, and G.Z. Xu Association between variant Y402H in age-related macular degeneration (AMD) susceptibility gene CFH and treatment response of AMD: a meta-analysis PLoS One 7 8 2012 e42464
268. G.S. Hageman, L.S. Hancox, and A.J. Taiber Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications Ann Med 38 8 2006 592 604
269. M.M. Liu, E. Agron, and E. Chew Copy number variations in candidate genes in neovascular age-related macular degeneration Invest Ophthalmol Vis Sci 52 6 2011 3129 3135
270. S.V. Goverdhan, M.W. Howell, and R.F. Mullins Association of HLA class I and class II polymorphisms with age-related macular degeneration Invest Ophthalmol Vis Sci 46 5 2005 1726 1734
271. B. Steen, S. Sejersen, L. Berglin, S. Seregard, and A. Kvanta Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes Invest Ophthalmol Vis Sci 39 11 1998 2194 2200
272. N. Fiotti, M. Pedio, and M. Battaglia Parodi MMP-9 microsatellite polymorphism and susceptibility to exudative form of age-related macular degeneration Genet Med 7 4 2005 272 277
273. K.Y. Chau, S. Sivaprasad, N. Patel, T.A. Donaldson, P.J. Luthert, and N.V. Chong Plasma levels of matrix metalloproteinase-2 and -9 (MMP-2 and MMP-9) in age-related macular degeneration Eye (Lond) 22 6 2008 855 859
274. E. Ryu, B.L. Fridley, N. Tosakulwong, K.R. Bailey, and A.O. Edwards Genome-wide association analyses of genetic, phenotypic, and environmental risks in the age-related eye disease study Mol Vis 16 2010 2811 2821
275. Y. Tong, J. Liao, Y. Zhang, J. Zhou, H. Zhang, and M. Mao LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis Mol Vis 16 2010 1958 1981
276. J.W. Crabb, M. Miyagi, and X. Gu Drusen proteome analysis: an approach to the etiology of age-related macular degeneration Proc Natl Acad Sci U S A 99 23 2002 14682 14687
277. E.M. Stone, T.A. Braun, and S.R. Russell Missense variations in the fibulin 5 gene and age-related macular degeneration N Engl J Med 351 4 2004 346 353
278. Eye Disease Case-Control Study Group Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group Arch Ophthalmol 110 12 1992 1701 1708
279. Eye Disease Case-Control Study Group Antioxidant status and neovascular age-related macular degeneration. Eye Disease Case-Control Study Group Arch Ophthalmol 111 1 1993 104 109
280. J.M. Seddon, U.A. Ajani, and R.D. Sperduto Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group JAMA 272 18 1994 1413 1420
281. J. Goldberg, G. Flowerdew, E. Smith, J.A. Brody, and M.O. Tso Factors associated with age-related macular degeneration. An analysis of data from the first National Health and Nutrition Examination Survey Am J Epidemiol 128 4 1988 700 710
282. G.M. VandenLangenberg, J.A. Mares-Perlman, R. Klein, B.E. Klein, W.E. Brady, and M. Palta Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the Beaver Dam Eye Study Am J Epidemiol 148 2 1998 204 214
283. Age-Related Eye Disease Study Research Group The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1 Control Clin Trials 20 6 1999 573 600
284. Age-Related Eye Disease Study Research Group The Age-Related Eye Disease Study: a clinical trial of zinc and antioxidants - Age-Related Eye Disease Study report no. 2 J Nutr 130 5S Suppl 2000 1516S 1519S
285. Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 Arch Ophthalmol 119 10 2001 1417 1436
286. L.M. Jampol Antioxidants, zinc, and age-related macular degeneration: results and recommendations Arch Ophthalmol 119 10 2001 1533 1534
287. D. Seigel AREDS investigators distort findings Arch Ophthalmol 120 1 2002 100 101
288. J. Ambati, and B.K. Ambati Age-related eye disease study caveats Arch Ophthalmol 120 7 2002 997 author reply 997-999
289. F. Ferris III, A.S. Lindblad, and R.C. Milton Age-related eye disease study caveats [author reply] Arch Ophthalmol 120 7 2002 997 author reply 997-999
290. R. van Leeuwen, S. Boekhoorn, and J.R. Vingerling Dietary intake of antioxidants and risk of age-related macular degeneration JAMA 294 24 2005 3101 3107
291. L. Ho, R. van Leeuwen, and J.C. Witteman Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and omega-3 fatty acids: the Rotterdam study Arch Ophthalmol 129 6 2011 758 766
292. M.D. Davis, R.E. Gangnon, and L.Y. Lee The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS report no. 17 Arch Ophthalmol 123 11 2005 1484 1498
293. F.L. Ferris, M.D. Davis, and T.E. Clemons A simplified severity scale for age-related macular degeneration: AREDS report no. 18 Arch Ophthalmol 123 11 2005 1570 1574
294. J.R. Evans Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration Cochrane Database Syst Rev 2 2006 CD000254
295. J. Evans Antioxidant supplements to prevent or slow down the progression of AMD: a systematic review and meta-analysis Eye (Lond) 22 6 2008 751 760
296. E.W. Chong, T.Y. Wong, A.J. Kreis, J.A. Simpson, and R.H. Guymer Dietary antioxidants and primary prevention of age related macular degeneration: systematic review and meta-analysis BMJ 335 7623 2007 755
297. J.R. Evans, and K. Henshaw Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration Cochrane Database Syst Rev 1 2008 CD000253
298. J.R. Evans, and J.G. Lawrenson Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration Cochrane Database Syst Rev 6 2012 CD000253
299. J.L. Haines, M.A. Hauser, and S. Schmidt Complement factor H variant increases the risk of age-related macular degeneration Science 308 5720 2005 419 421
300. A.O. Edwards, R. Ritter 3rd, K.J. Abel, A. Manning, C. Panhuysen, and L.A. Farrer Complement factor H polymorphism and age-related macular degeneration Science 308 5720 2005 421 424
301. R.J. Klein, C. Zeiss, and E.Y. Chew Complement factor H polymorphism in age-related macular degeneration Science 308 5720 2005 385 389
302. G.S. Hageman, D.H. Anderson, and L.V. Johnson A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration Proc Natl Acad Sci U S A 102 20 2005 7227 7232
303. S. Zareparsi, K.E. Branham, and M. Li Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration Am J Hum Genet 77 1 2005 149 153
304. M.L. Klein, P.J. Francis, and B. Rosner CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration Ophthalmology 115 6 2008 1019 1025
305. A.R. Johnson, A. Munoz, J.L. Gottlieb, and D.F. Jarrard High dose zinc increases hospital admissions due to genitourinary complications J Urol 177 2 2007 639 643
306. G. Caire-Juvera, C. Ritenbaugh, J. Wactawski-Wende, L.G. Snetselaar, and Z. Chen Vitamin A and retinol intakes and the risk of fractures among participants of the Women's Health Initiative Observational Study Am J Clin Nutr 89 1 2009 323 330
307. S. Sahni, M.T. Hannan, J. Blumberg, L.A. Cupples, D.P. Kiel, and K.L. Tucker Protective effect of total carotenoid and lycopene intake on the risk of hip fracture: a 17-year follow-up from the Framingham Osteoporosis Study J Bone Miner Res 24 6 2009 1086 1094
308. E.A. Klein, I.M. Thompson Jr., and C.M. Tangen Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT) JAMA 306 14 2011 1549 1556
309. J.M. Gaziano, R.J. Glynn, and W.G. Christen Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial JAMA 301 1 2009 52 62
310. D. Albanes, O.P. Heinonen, and J.K. Huttunen Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study Am J Clin Nutr 62 6 Suppl 1995 1427S 1430S
311. National Eye Institute (NEI). The AREDS formulation and age-related macular degeneration: are these high levels of antioxidants and zinc right for you? Available at: http://www.nei.nih.gov/amd/summary.asp. Accessed October 15, 2012.
312. S.M. Moeller, N. Parekh, and L. Tinker Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women's Health Initiative Arch Ophthalmol 124 8 2006 1151 1162
313. J.S. Tan, J.J. Wang, V. Flood, E. Rochtchina, W. Smith, and P. Mitchell Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study Ophthalmology 115 2 2008 334 341
314. J.P. SanGiovanni, E.Y. Chew, and T.E. Clemons The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS report no. 22 Arch Ophthalmol 125 9 2007 1225 1232
315. E.Y. Chew, T. Clemons, and J.P. Sangiovanni The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1) Ophthalmology 119 11 2012 2282 2289
316. N. Krishnadev, A.D. Meleth, and E.Y. Chew Nutritional supplements for age-related macular degeneration Curr Opin Ophthalmol 21 3 2010 184 189
317. E.Y. Chew Fatty acids and retinopathy N Engl J Med 364 20 2011 1970 1971
318. National Eye Institute (NEI). Age-Related Eye Disease Study 2 (AREDS2). In: ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/ NCT00345176. Accessed October 15, 2012.
319. K.M. Connor, J.P. SanGiovanni, and C. Lofqvist Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis Nat Med 13 7 2007 868 873
320. A. Stahl, P. Sapieha, and K.M. Connor Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy Circ Res 107 4 2010 495 500
321. P. Sapieha, A. Stahl, and J. Chen 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of omega-3 polyunsaturated fatty acids Sci Transl Med 3 69 2011 69ra12
322. P.T. de Jong, U. Chakravarthy, and M. Rahu Associations between aspirin use and aging macula disorder: the European Eye Study Ophthalmology 119 1 2012 112 118
323. W.G. Christen, R.J. Glynn, and U.A. Ajani Age-related maculopathy in a randomized trial of low-dose aspirin among US physicians Arch Ophthalmol 119 8 2001 1143 1149
324. W.G. Christen, R.J. Glynn, E.Y. Chew, and J.E. Buring Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women Ophthalmology 116 12 2009 2386 2392
325. R.H. Guymer, P.N. Dimitrov, and M. Varsamidis Can HMG Co-A reductase inhibitors ("statins") slow the progression of age-related macular degeneration? The Age-Related Maculopathy Statin Study (ARMSS) Clin Interv Aging 3 3 2008 581 593
326. C.A. Curcio, M. Johnson, M. Rudolf, and J.D. Huang The oil spill in ageing Bruch membrane Br J Ophthalmol 95 12 2011 1638 1645
327. N. Kaiserman, S. Vinker, and I. Kaiserman Statins do not decrease the risk for wet age-related macular degeneration Curr Eye Res 34 4 2009 304 310
328. D.S. Fong, and R. Contreras Recent statin use and 1-year incidence of exudative age-related macular degeneration Am J Ophthalmol 149 6 2010 955 958.e1
329. G. McGwin Jr., A. Xie, and C. Owsley The use of cholesterol-lowering medications and age-related macular degeneration Ophthalmology 112 3 2005 488 494
330. M. Etminan, J.M. Brophy, and D. Maberley Use of statins and angiotensin converting enzyme inhibitors (ACE-Is) and the risk of age-related macular degeneration: nested case-control study Curr Drug Saf 3 1 2008 24 26
331. M.G. Maguire, G.S. Ying, C.A. McCannel, C. Liu, and Y. Dai Statin use and the incidence of advanced age-related macular degeneration in the Complications of Age-Related Macular Degeneration Prevention Trial Ophthalmology 116 12 2009 2381 2385
332. R. Klein, Y. Deng, and B.E. Klein Cardiovascular disease, its risk factors and treatment, and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary study Am J Ophthalmol 143 3 2007 473 483
333. V. Shalev, M. Sror, I. Goldshtein, E. Kokia, and G. Chodick Statin use and the risk of age related macular degeneration in a large health organization in Israel Ophthalmic Epidemiol 18 2 2011 83 90
334. P. Gehlbach, T. Li, and E. Hatef Statins for age-related macular degeneration Cochrane Database Syst Rev 3 2012 CD006927
335. J.D. Gass Drusen and disciform macular detachment and degeneration Arch Ophthalmol 90 3 1973 206 217
336. G.W. Cleasby, A.S. Nakanishi, and J.L. Norris Prophylactic photocoagulation of the fellow eye in exudative senile maculopathy. A preliminary report Mod Probl Ophthalmol 20 1979 141 147
337. P.C. Wetzig Photocoagulation of drusen-related macular degeneration: a long-term outcome Trans Am Ophthalmol Soc 92 1994 299 303 discussion 303-306
338. M. Gross-Jendroska, S.L. Owens, C.J. Flaxel, R.H. Guymer, and A.C. Bird Prophylactic laser treatment to fellow eyes of unilateral retinal pigment epithelial tears Am J Ophthalmol 126 1 1998 77 81
339. M.B. Parodi, G. Virgili, and J.R. Evans Laser treatment of drusen to prevent progression to advanced age-related macular degeneration Cochrane Database Syst Rev 3 2009 CD006537
340. F. Treumer, A. Klettner, and J. Baltz Vectorial release of matrix metalloproteinases (MMPs) from porcine RPE-choroid explants following selective retina therapy (SRT): towards slowing the macular ageing process Exp Eye Res 97 1 2012 63 72
341. J.J. Zhang, Y. Sun, A.A. Hussain, and J. Marshall Laser-mediated activation of human retinal pigment epithelial cells and concomitant release of matrix metalloproteinases Invest Ophthalmol Vis Sci 53 6 2012 2928 2937
342. S.L. Fine Age-related macular degeneration 1969-2004: a 35-year personal perspective Am J Ophthalmol 139 3 2005 405 420
343. Macular Photocoagulation Study Group Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group Arch Ophthalmol 109 8 1991 1109 1114
344. Macular Photocoagulation Study Group Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group Arch Ophthalmol 108 6 1990 816 824
345. Macular Photocoagulation Study Group Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Macular Photocoagulation Study Group Arch Ophthalmol 104 5 1986 694 701
346. Macular Photocoagulation Study Group Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group Arch Ophthalmol 111 9 1993 1200 1209
347. M.A. Thomas, and H.J. Kaplan Surgical removal of subfoveal neovascularization in the presumed ocular histoplasmosis syndrome Am J Ophthalmol 111 1 1991 1 7
348. A. Uemura, and M.A. Thomas Visual outcome after surgical removal of choroidal neovascularization in pediatric patients Arch Ophthalmol 118 10 2000 1373 1378
349. B.S. Hawkins, N.M. Bressler, and P.H. Miskala Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11 Ophthalmology 111 11 2004 1967 1980
350. R. Machemer Macular translocation Am J Ophthalmol 125 5 1998 698 700
351. M.R. Romano, X. Valldeperas, P. Vinciguerra, and D. Wong Sub-macular surgery: is still an option for age-related macular degeneration? Curr Drug Targets 12 2 2011 190 198
352. F. Giansanti, C.M. Eandi, and G. Virgili Submacular surgery for choroidal neovascularisation secondary to age-related macular degeneration Cochrane Database Syst Rev 2 2009 CD006931
353. M.T. Cahill, P. Mruthyunjaya, C. Bowes Rickman, and C.A. Toth Recurrence
354. C.A. Baer, C.B. Rickman, S. Srivastava, G. Malek, S. Stinnett, and C.A. Toth Recurrent choroidal neovascularization after macular translocation surgery with 360-degree peripheral retinectomy Retina 28 9 2008 1221 1227
355. D.M. Marcus, E. Peskin, and M. Maguire The age-related macular degeneration radiotherapy trial (AMDRT): one year results from a pilot study Am J Ophthalmol 138 5 2004 818 828
356. D.M. Marcus, W.C. Sheils, and J.O. Young Radiotherapy for recurrent choroidal neovascularisation complicating age related macular degeneration Br J Ophthalmol 88 1 2004 114 119
357. D.M. Marcus, W. Sheils, and M.H. Johnson External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double-masked, randomized clinical trial Arch Ophthalmol 119 2 2001 171 180
358. D.M. Marcus, M.W. Camp, and W.C. Sheils Sham radiation in clinical trials assessing radiotherapy for exudative age-related macular degeneration Retina 19 6 1999 525 530
359. M.R. Stevenson, P.M. Hart, and U. Chakravarthy Visual functioning and quality of life in the SubFoveal Radiotherapy Study (SFRADS): SFRADS report 2 Br J Ophthalmol 89 8 2005 1045 1051
360. P.M. Hart, U. Chakravarthy, and G. Mackenzie Visual outcomes in the subfoveal radiotherapy study: a randomized controlled trial of teletherapy for age-related macular degeneration Arch Ophthalmol 120 8 2002 1029 1038
361. U. Chakravarthy, and G. MacKenzie External beam radiotherapy in exudative age-related macular degeneration: a pooled analysis of phase I data Br J Radiol 73 867 2000 305 313
362. D.H. Char, A.I. Irvine, M.D. Posner, J. Quivey, T.L. Phillips, and S. Kroll Randomized trial of radiation for age-related macular degeneration Am J Ophthalmol 127 5 1999 574 578
363. H.J. Zambarakji, A.M. Lane, and E. Ezra Proton beam irradiation for neovascular age-related macular degeneration Ophthalmology 113 11 2006 2012 2019
364. King's College Hospital NHS Trust. Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT). In: ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/NCT01006538. Accessed October 15, 2012.
365. NeoVista. A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration (CABERNET). In: ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/NCT00454389. Accessed October 15, 2012.
366. NeoVista. A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy (MERITAGE). In: ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/NCT00809419. Accessed October 15, 2012.
367. M.P. Avila, M.E. Farah, and A. Santos Twelve-month safety and visual acuity results from a feasibility study of intraocular, epiretinal radiation therapy for the treatment of subfoveal CNV secondary to AMD Retina 29 2 2009 157 169
368. M.P. Avila, M.E. Farah, A. Santos, J.P. Duprat, B.W. Woodward, and J. Nau Twelve-month short-term safety and visual-acuity results from a multicentre prospective study of epiretinal strontium-90 brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularisation secondary to age-related macular degeneration Br J Ophthalmol 93 3 2009 305 309
369. A.A. Moshfeghi, V.M. Canton, and H. Quiroz-Mercado 16-Gy low-voltage x-ray irradiation followed by as-needed ranibizumab therapy for AMD: 6-month outcomes of a "radiation-first" strategy Ophthalmic Surg Lasers Imaging 42 6 2011 460 467
370. J.B. Jonas, U.H. Spandau, B. Harder, U. Vossmerbaeumer, and B.A. Kamppeter Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide Am J Ophthalmol 139 6 2005 1073 1079
371. M.C. Gillies, and J. Larsson The effect of intravitreal triamcinolone on foveal edema in exudative macular degeneration Am J Ophthalmol 144 1 2007 134 136
372. A. Geltzer, A. Turalba, and S.S. Vedula Surgical implantation of steroids with antiangiogenic characteristics for treating neovascular age-related macular degeneration Cochrane Database Syst Rev 4 2007 CD005022
373. R.F. Spaide, J. Sorenson, and L. Maranan Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization Ophthalmology 112 2 2005 301 304
374. R.F. Spaide, J. Sorenson, and L. Maranan Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization Ophthalmology 110 8 2003 1517 1525
375. J.W. Miller, A.W. Walsh, and M. Kramer Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin Arch Ophthalmol 113 6 1995 810 818
376. M. Kramer, J.W. Miller, and N. Michaud Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys Ophthalmology 103 3 1996 427 438
377. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Arch Ophthalmol 117 10 1999 1329 1345
378. M.A. Mainster, and E. Reichel Transpupillary thermotherapy for age-related macular degeneration: long-pulse photocoagulation, apoptosis, and heat shock proteins Ophthalmic Surg Lasers 31 5 2000 359 373
379. J.G. Journee-de Korver, and J.E. Keunen Thermotherapy in the management of choroidal melanoma Prog Retin Eye Res 21 3 2002 303 317
380. B.M. Stoffelns, K. Schoepfer, J. Vetter, A. Mirshahi, and H. Elflein [Long-term follow-up 10 years after transpupillary thermotherapy (TTT) for small, posterior located malignant melanomas of the choroid] Klin Monbl Augenheilkd 228 4 2011 277 283
381. A.H. Rogers, and E. Reichel Transpupillary thermotherapy of subfoveal occult choroidal neovascularization Curr Opin Ophthalmol 12 3 2001 212 215
382. C.H. Park, J.S. Duker, M.A. Mainster, C.A. Puliafito, and E. Reichel Transpupillary thermotherapy (TTT) of occult choroidal neovascularization: a retrospective, noncomparative case series of fifty-seven eyes Semin Ophthalmol 16 2 2001 66 69
383. R.M. Ahuja, J.D. Benner, J.C. Schwartz, J.W. Butler, and S.M. Steidl Efficacy of transpupillary thermotherapy (TTT) in the treatment of occult subfoveal choroidal neovascularization in age-related macular degeneration Semin Ophthalmol 16 2 2001 81 85
384. Results from pivotal clinical trials released at AAO meeting: specialists comment on their significance Retinal Physician 2005(January) e100045
385. E.S. Gragoudas, A.P. Adamis, E.T. Cunningham Jr., M. Feinsod, and D.R. Guyer Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 27 2004 2805 2816
386. P.J. Rosenfeld, D.M. Brown, and J.S. Heier Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1419 1431
387. P.J. Rosenfeld Bevacizumab versus ranibizumab for AMD N Engl J Med 364 20 2011 1966 1967
388. CATT Research Group D.F. Martin, and M.G. Maguire Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 20 2011 1897 1908
389. CATT Research Group D.F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 7 2012 1388 1398
390. A.J. Lotery CATT, meet IVAN: what have we learned from the ongoing ranibizumab vs bevacizumab trials? Retinal Physician 2012(June) e107120
391. M.S. Ip, I.U. Scott, and G.C. Brown Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology Ophthalmology 115 10 2008 1837 1846
392. S. Gonzalez, P.J. Rosenfeld, M.W. Stewart, J. Brown, and S.P. Murphy Avastin doesn't blind people, people blind people Am J Ophthalmol 153 2 2012 196e1 203e1
393. M.W. Stewart, S. Grippon, and P. Kirkpatrick Aflibercept Nat Rev Drug Discov 11 4 2012 269 270
394. United States Food and Drug Administration (FDA). FDA labeling information - Eylea. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/label/2011/1253871bl.pdf. Accessed October 1, 2012.
395. P. Pechan, H. Rubin, and M. Lukason Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization Gene Ther 16 1 2009 10 16
396. T.K. Maclachlan, M. Lukason, and M. Collins Preclinical safety evaluation of AAV2-sFLT01: a gene therapy for age-related macular degeneration Mol Ther 19 2 2011 326 334
397. C.M. Lai, M.J. Estcourt, and R.P. Himbeck Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates Gene Ther 19 10 2012 999 1009
398. Genzyme (Sanofi). Safety and Tolerability Study of AAV2-sFLT01 in Patients with Neovascular Age-Related Macular Degeneration (AMD). In: ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/ NCT01024998. Accessed October 15, 2012.
399. Ophthotech, Corp Ophthotech's Novel Anti-PDGF Combination Agent Fovista™ Demonstrated Superior Efficacy over Lucentis® Monotherapy in Large Controlled Wet AMD Trial [press release] 2012 Ophthotech Princeton, NJ
400. K. Binley, P.S. Widdowson, and M. Kelleher Safety and biodistribution of an EIAV-based gene therapy, RetinoStat(R), for age-related macular degeneration Hum Gene Ther 23 9 2012 980 991
401. A.G. Marneros, D.R. Keene, and U. Hansen Collagen XVIII/endostatin is essential for vision and retinal pigment epithelial function EMBO J 23 1 2004 89 99
402. I.A. Bhutto, S.Y. Kim, and D.S. McLeod Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with age-related macular degeneration Invest Ophthalmol Vis Sci 45 5 2004 1544 1552
403. O. Tatar, K. Shinoda, and A. Adam Expression of endostatin in human choroidal neovascular membranes secondary to age-related macular degeneration Exp Eye Res 83 2 2006 329 338
404. I.A. Bhutto, K. Uno, C. Merges, L. Zhang, D.S. McLeod, and G.A. Lutty Reduction of endogenous angiogenesis inhibitors in Bruch's membrane of the submacular region in eyes with age-related macular degeneration Arch Ophthalmol 126 5 2008 670 678
405. K. Mori, A. Ando, and P. Gehlbach Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin Am J Pathol 159 1 2001 313 320
406. C.C. Lai, W.C. Wu, and S.L. Chen Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin Invest Ophthalmol Vis Sci 42 10 2001 2401 2407
407. A. Auricchio, K.C. Behling, and A.M. Maguire Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents Mol Ther 6 4 2002 490 494
408. K. Takahashi, Y. Saishin, and Y. Saishin Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment FASEB J 17 8 2003 896 898
409. K.S. Balaggan, K. Binley, and M. Esapa EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV Gene Ther 13 15 2006 1153 1165
410. S. Kachi, K. Binley, and K. Yokoi Equine infectious anemia viral vector-mediated codelivery of endostatin and angiostatin driven by retinal pigmented epithelium-specific VMD2 promoter inhibits choroidal neovascularization Hum Gene Ther 20 1 2009 31 39
411. P.A. Campochiaro Gene transfer for ocular neovascularization and macular edema Gene Ther 19 2 2012 121 126
412. Q.L. Shang, J.X. Ma, J.S. Wei, Z.L. Shang, H.M. Xiu, and A.Q. Yang [Experimental choroidal neovascularization is inhibited by subretinal administration of Endostatin] Zhonghua Yan Ke Za Zhi 40 4 2004 266 271
413. A.G. Marneros, H. She, and H. Zambarakji Endogenous endostatin inhibits choroidal neovascularization FASEB J 21 14 2007 3809 3818
414. Oxford BioMedica. Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD) (GEM). In: ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/NCT01301443. Accessed October 1, 2012.
415. M. Kono, Y. Mi, and Y. Liu The sphingosine-1-phosphate receptors S1P1, S1P2, and S1P3 function coordinately during embryonic angiogenesis J Biol Chem 279 28 2004 29367 29373
416. LPath, Inc. iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects with Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV). In: ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/NCT01334255. Accessed October 15, 2012.
417. LPath, Inc. Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-Related Macular Degeneration. In: ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/NCT00767949. Accessed October 15, 2012.
418. LPath, Inc., Pfizer. Efficacy and Safety Study of iSONEP with and without Lucentis/Avastin to Treat Age-Related Macular Degeneration (AMD) (Nexus). In: ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/ NCT01414153. Accessed October 15, 2012.
419. R.M. Bukowski, U. Yasothan, and P. Kirkpatrick Pazopanib Nat Rev Drug Discov 9 1 2010 17 18
420. Y. Yafai, X.M. Yang, and M. Niemeyer Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats Eur J Pharmacol 666 1-3 2011 12 18
421. M. Kernt, S. Thiele, and A.S. Neubauer Inhibitory Activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2 Retina 32 8 2012 1652 1663
422. L. Charters Pazopanib explored for neovascular age-related macular degeneration Ophthalmology Times 2010;March 1
423. GlaxoSmithKline. A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration. In: ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/NCT01154062. Accessed October 15, 2012.
424. Potentia Pharmaceuticals Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II [press release] May 4, 2009 Potentia Pharmaceuticals Louisville, KY
425. V. Tarallo, Y. Hirano, and B.D. Gelfand DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88 Cell 149 4 2012 847 859
426. T. Fulmer Eyeing the inflammasome SciBX 5 20 2012 1 3
427. S.L. Doyle, M. Campbell, and E. Ozaki NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components Nat Med 18 5 2012 791 798
428. J.R. Sparrow, K. Nakanishi, and C.A. Parish The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells Invest Ophthalmol Vis Sci 41 7 2000 1981 1989
429. J.R. Sparrow, and B. Cai Blue light-induced apoptosis of A2E-containing RPE: involvement of caspase-3 and protection by Bcl-2 Invest Ophthalmol Vis Sci 42 6 2001 1356 1362
430. J.R. Sparrow, and M. Boulton RPE lipofuscin and its role in retinal pathobiology Exp Eye Res 80 5 2005 595 606
431. J.R. Sparrow, Y. Wu, T. Nagasaki, K.D. Yoon, K. Yamamoto, and J. Zhou Fundus autofluorescence and the bisretinoids of retina Photochem Photobiol Sci 9 11 2010 1480 1489
432. ReVision Therapeutics Inc. Phase 2b Data Suggest ReVision's Oral Fenretinide (RT-101) Slows Lesion Growth, Preserves Vision and Reduces Incidence of Neovascularization in Geographic Atrophy Patients [press release]. ReVision Therapeutics, San Diego, CA; October 10, 2010.
433. R.A. Radu, Y. Han, and T.V. Bui Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases Invest Ophthalmol Vis Sci 46 12 2005 4393 4401
434. M. Karmel News in review: fenretinide fights dry AMD EyeNet Magazine October 2010
435. A. Maeda, T. Maeda, and M. Golczak Effects of potent inhibitors of the retinoid cycle on visual function and photoreceptor protection from light damage in mice Mol Pharmacol 70 4 2006 1220 1229
436. R. Kubota, N.L. Boman, R. David, S. Mallikaarjun, S. Patil, and D. Birch Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator Retina 32 1 2012 183 188
437. J.D. Ding, L.V. Johnson, and R. Herrmann Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration Proc Natl Acad Sci U S A 108 28 2011 E279 E287
438. W.T. Wong, W. Kam, and D. Cunningham Treatment of geographic atrophy by the topical administration of OT-551: results of a phase II clinical trial Invest Ophthalmol Vis Sci 51 12 2010 6131 6139
439. P.A. Sieving, R.C. Caruso, and W. Tao Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants Proc Natl Acad Sci U S A 103 10 2006 3896 3901
440. R.J. Collier, Y. Patel, and E.A. Martin Agonists at the serotonin receptor (5-HT(1A)) protect the retina from severe photo-oxidative stress Invest Ophthalmol Vis Sci 52 5 2011 2118 2126
441. F.M. Damico, F. Gasparin, M.R. Scolari, L.S. Pedral, and B.S. Takahashi New approaches and potential treatments for dry age-related macular degeneration Arq Bras Oftalmol 75 1 2012 71 76
442. Allergan. Safety and Efficacy of Brimonidine Intravitreal Implant in Patients with Geographic Atrophy Due to Age-Related Macular Degeneration (AMD). In: ClinicalTrials.gov. Available at: http://clinicaltrials.gov/ct2/show/ NCT00658619. Accessed October 15, 2012.
443. Y. Murakami, J.W. Miller, and D.G. Vavvas RIP kinase-mediated necrosis as an alternative mechanisms of photoreceptor death Oncotarget 2 6 2011 497 509
444. G. Trichonas, Y. Murakami, and A. Thanos Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis Proc Natl Acad Sci U S A 107 50 2010 21695 21700
445. J. Suzuki, A. Manola, and Y. Murakami Inhibitory effect of aminoimidazole carboxamide ribonucleotide (AICAR) on endotoxin-induced uveitis in rats Invest Ophthalmol Vis Sci 52 9 2011 6565 6571
446. T. Nakazawa, M. Kayama, and M. Ryu Tumor necrosis factor-alpha mediates photoreceptor death in a rodent model of retinal detachment Invest Ophthalmol Vis Sci 52 3 2011 1384 1391
447. S.D. Schwartz, J.P. Hubschman, and G. Heilwell Embryonic stem cell trials for macular degeneration: a preliminary report Lancet 379 9817 2012 713 720
448. N.D. Radtke, R.B. Aramant, H.M. Petry, P.T. Green, D.J. Pidwell, and M.J. Seiler Vision improvement in retinal degeneration patients by implantation of retina together with retinal pigment epithelium Am J Ophthalmol 146 2 2008 172 182
449. K. Gertow, J. Cedervall, and S. Jamil Early events in xenograft development from the human embryonic stem cell line HS181 - resemblance with an initial multiple epiblast formation PLoS One 6 11 2011 e27741
450. K. Deisseroth Optogenetics Nat Methods 8 1 2011 26 29
451. P.S. Lagali, D. Balya, and G.B. Awatramani Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration Nat Neurosci 11 6 2008 667 675
452. B. Lin, R.H. Masland, and E. Strettoi Remodeling of cone photoreceptor cells after rod degeneration in rd mice Exp Eye Res 88 3 2009 589 599
453. M.M. Doroudchi, K.P. Greenberg, and J. Liu Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness Mol Ther 19 7 2011 1220 1229
454. M. Fradot, V. Busskamp, and V. Forster Gene therapy in ophthalmology: validation on cultured retinal cells and explants from postmortem human eyes Hum Gene Ther 22 5 2011 587 593
455. M.A. Singer, N. Amir, A. Herro, S.S. Porbandarwalla, and J. Pollard Improving quality of life in patients with end-stage age-related macular degeneration: focus on miniature ocular implants Clin Ophthalmol 6 2012 33 39